• Consensus Rating: Buy
  • Consensus Price Target: $10.67
  • Forecasted Upside: 70.12%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$6.27
▲ +0.16 (2.62%)

This chart shows the closing price for AXGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AxoGen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AXGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AXGN

Analyst Price Target is $10.67
▲ +70.12% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for AxoGen in the last 3 months. The average price target is $10.67, with a high forecast of $12.00 and a low forecast of $9.00. The average price target represents a 70.12% upside from the last price of $6.27.

This chart shows the closing price for AXGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in AxoGen. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/19/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$12.00Low
12/7/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$11.00Low
10/16/2023SVB LeerinkInitiated CoverageOutperform$9.00Low
9/26/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$16.00Low
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$16.00Low
3/28/2023Canaccord Genuity GroupReiterated RatingBuy$15.00Low
3/15/2023JMP SecuritiesReiterated RatingMarket Outperform$20.00Low
11/11/2022Jefferies Financial GroupReiterated RatingBuy$15.00Low
11/9/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$15.00 ➝ $18.00Low
5/9/2022Canaccord Genuity GroupUpgradeHold ➝ Buy$10.00 ➝ $15.00High
2/23/2022Canaccord Genuity GroupLower TargetHold ➝ Hold$15.00 ➝ $12.00High
11/4/2021JMP SecuritiesReiterated RatingBuy$25.00 ➝ $20.00High
10/22/2021SVB LeerinkReiterated RatingOutperformHigh
5/31/2021SVB LeerinkReiterated RatingBuy$27.00Medium
2/23/2021SVB LeerinkBoost TargetOutperform$23.00 ➝ $27.00Medium
1/12/2021Cantor FitzgeraldBoost TargetOverweight$16.00 ➝ $23.00High
10/22/2020GuggenheimInitiated CoverageBuy$24.00Low
8/6/2020SVB LeerinkBoost TargetOutperform$13.50 ➝ $15.50High
8/5/2020BTIG ResearchReiterated RatingHoldHigh
7/1/2020BTIG ResearchDowngradeHoldHigh
6/15/2020Cantor FitzgeraldInitiated CoverageBuy$16.00Low
6/8/2020Cantor FitzgeraldReiterated RatingOverweightLow
4/2/2020BTIG ResearchDowngradeBuy ➝ NeutralHigh
12/16/2019BTIG ResearchReiterated RatingBuy$21.00High
8/7/2019JMP SecuritiesLower TargetOutperform$43.00 ➝ $28.00Medium
8/7/2019BTIG ResearchLower TargetBuy$21.00High
8/7/2019William BlairDowngradeOutperform ➝ Market PerformHigh
8/7/2019Cantor FitzgeraldLower TargetOverweight$30.00 ➝ $21.00High
(Data available from 5/27/2019 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2023
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/28/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/28/2023
  • 6 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/27/2024
  • 6 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/26/2024
  • 11 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2024
  • 6 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/26/2024

Current Sentiment

  • 6 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
AxoGen logo
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
Read More

Today's Range

Now: $6.27
Low: $6.05
High: $6.28

50 Day Range

MA: $6.86
Low: $5.67
High: $8.07

52 Week Range

Now: $6.27
Low: $3.45
High: $10.83

Volume

235,000 shs

Average Volume

379,276 shs

Market Capitalization

$274.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07

Frequently Asked Questions

What sell-side analysts currently cover shares of AxoGen?

The following Wall Street research analysts have issued reports on AxoGen in the last twelve months: Canaccord Genuity Group Inc., Cantor Fitzgerald, StockNews.com, and SVB Leerink LLC.
View the latest analyst ratings for AXGN.

What is the current price target for AxoGen?

3 Wall Street analysts have set twelve-month price targets for AxoGen in the last year. Their average twelve-month price target is $10.67, suggesting a possible upside of 70.1%. Cantor Fitzgerald has the highest price target set, predicting AXGN will reach $12.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $9.00 for AxoGen in the next year.
View the latest price targets for AXGN.

What is the current consensus analyst rating for AxoGen?

AxoGen currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AXGN will outperform the market and that investors should add to their positions of AxoGen.
View the latest ratings for AXGN.

What other companies compete with AxoGen?

Other companies that are similar to AxoGen include Edap Tms, Zynex, Outset Medical, Semler Scientific and Electromed. Learn More about companies similar to AxoGen.

How do I contact AxoGen's investor relations team?

AxoGen's physical mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider's listed phone number is (386) 462-6800 and its investor relations email address is [email protected]. The official website for AxoGen is www.axogeninc.com. Learn More about contacing AxoGen investor relations.